In a filing, ANI Pharmaceuticals Inc. revealed its HEAD OF R&D, COO-NOVITIUM OPS Shanmugam Muthusamy unloaded Company’s shares for reported $1.58 million on Aug 29. In the deal valued at $63.37 per share,25,000 shares were sold. As a result of this transaction, Shanmugam Muthusamy now holds 1,132,620 shares worth roughly $ 73.14 million.
Then, Shanmugam Muthusamy sold 25,000 shares, generating $1,576,500 in total proceeds. Upon selling the shares at $63.06, the HEAD OF R&D, COO-NOVITIUM OPS now owns 1,157,620 shares.
Before that, Gutwerg Ori sold 15,561 shares. ANI Pharmaceuticals Inc. shares valued at $970,851 were divested by the SVP, GENERICS at a price of $62.39 per share. As a result of the transaction, Gutwerg Ori now holds 60,915 shares, worth roughly $3.93 million.
H.C. Wainwright reiterated its ANI Pharmaceuticals Inc. [ANIP] rating to a Buy in a research note published on Friday, August 22, 2023; the price target was $73. PT values the company’s stock at a premium of 11.53 to its Friday closing price.
Price Performance Review of ANIP
On Friday, ANI Pharmaceuticals Inc. [NASDAQ:ANIP] saw its stock jump 0.30% to $64.58. On the same session, the stock had its day’s lowest price of $64.10, but rose to a high of $65.89. Over the last five days, the stock has gained 1.21%. ANI Pharmaceuticals Inc. shares have risen nearly 60.53% since the year began. Nevertheless, the stocks have risen 75.06% over the past one year. While a 52-week high of $64.85 was reached on 09/01/23, a 52-week low of $30.53 was recorded on 03/24/23. SMA at 50 days reached $55.95, while 200 days put it at $45.51. A total of 0.19 million shares were traded, compared to the trading of 0.25 million shares in the previous session.
Levels Of Support And Resistance For ANIP Stock
The 24-hour chart illustrates a support level at 63.82, which if violated will result in even more drops to 63.07. On the upside, there is a resistance level at 65.61. A further resistance level may holdings at 66.65. The Relative Strength Index (RSI) on the 14-day chart is 69.33, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.99, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 17.37%. Stochastics %K at 90.72% indicates the stock is a selling.
How much short interest is there in ANI Pharmaceuticals Inc.?
A steep rise in short interest was recorded in ANI Pharmaceuticals Inc. stocks on Aug 14, 2023, dropping by 60050.0 shares to a total of 0.29 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 0.35 million shares. There was a decline of -20.98%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 2.13% of the overall stock float, the days-to-cover ratio (short ratio) fell to 2.55.
ANI Pharmaceuticals Inc. [ANIP] – Who Are The Largest Shareholders?
In filings from BlackRock Fund Advisors, it is revealed that the company now owns 1,995,229 shares, or roughly 11.11% of the outstanding ANIP shares. In other words, the investor’s shares have risen by 189,596 from its previous 13-F filing of 1805633.0. Additionally, The Vanguard Group, Inc. increased 27.91% of its stake after which the total value it holdings stand at $54,721,734, while Rubric Capital Management LP added 30.70% of its stake to hold $44.51 million in the firm. Over the last quarter, Dimensional Fund Advisors LP purchased 12,750 shares of ANI Pharmaceuticals Inc., while William Blair Investment Manageme bought 9,998 shares. At present, Medical Strategy GmbH is holding 515,672 shares valued at $27.1 million. Deep Track Capital LP owned 514,021 shares of the company at the time of its most recent 13F filing, worth $27.01 million.
According to FactSet, ANI Pharmaceuticals Inc.’s share price will average $71.67 in the next year, based on opinions of analysts polled by the firm. This is up nearly 11.82 percent from its previous closing price of $64.39. Analysts expect ANI Pharmaceuticals Inc. stock to reach the higher price of $73.00, while the lowest price estimate is $70.00. However, 3 analysts have rated ANIP stock as a Buy in their predictions for 2023.